loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

INTEGRIS MEDTECH IPO

UPCOMING

IPO Details

27th Nov 2026
1st Dec 2026
0
₹ 0
₹ 0-0
₹ 925 Crore

Issue timeline

  • 27 Nov-1 Dec 2026
  • 02-Dec-2026
  • 03-Dec-2026
  • 03-Dec-2026
  • 04-Dec-2026

About Company

Integris Medtech was incorporated on April 25, 2008. The company is a diversified India-based global MedTech and laboratory solutions provider, specialising in medical devices, diagnostics, and lab solutions. It is India’s second-largest coronary stent maker (22% DES market share) and Southeast Asia’s largest scientific laboratory solutions company
-
Name Designation
Annaswamy Vaidheesh Chairperson & Non-Executive Independent Director
Probir Das Executive Director & Group Chief Executive Officer
Rajani Kesari Non-Executive Independent Director
Ramesh Subrahmanian Non-Executive Independent Director
Gurmit Singh Chugh Non-Executive Director
Avnish Mehra Non-Executive Nominee Director
Punita Sharma Non-Executive Director
Arjun Oberoi Non-Executive Nominee Director
Vishal Omprakash Goenka Non-Executive Nominee Director

Objectives

Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued, and prepayment penalties, as applicable, availed by their wholly-owned Subsidiaries, namely, Translumina Therapeutics (“Translumina Therapeutics”), Transhealth (“Transhealth”), and HaleMed Medical 
Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued, and prepayment penalties, as applicable, availed by their step-down subsidiaries, namely, CPC Diagnostics, Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd.
General corporate purposes

Strengths & Risks

Strengths (3)

The company operates a diversified global MedTech platform spanning research, diagnostics, and healthcare delivery. It supplies equipment and consumables to over 9,500 labs across Asia and serves major diagnostic chains like Dr. Lal Path Labs, Neuberg Labs, and Metropolis Healthcare

Risks (3)

The company must obtain and maintain various statutory and regulatory approvals to operate its business. Delays or failures in securing these could impact product sales and operations, as its MedTech and lab solutions activities are subject to complex regulations across India and global markets

Financials

Frequently Asked Questions

Who are the promoters of Integris Medtech Ltd.?

The promoters of the company are Evercure Holdings Pte. Ltd. and Medicore Holdings Pte. Ltd..

The category allocation of qualified institutional buyers is 75.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 10.0%.

The IPO application opens on Nov 27, 2026 and closes on Dec 01, 2026.

This IPO will be allotted on Dec 02, 2026.

The refund will be credited to your account on Dec 03, 2026.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.